Diagnostic testing company Adaptive has bought Celgene-backed blood cancers test developer Sequenta in a deal backed by $94m of private equity money.

Cancer research technology company Adaptive Biotechnologies Corporation acquired US-based clinical diagnostics technology developer Sequenta yesterday, providing an exit to pharmaceutical firm Celgene.

Although the purchase price for Sequenta has not been disclosed, Puget Sound Business Journal reported that Adaptive recently raised $94m in private equity to fund the transaction.

Celgene invested an undisclosed amount in Sequenta in October 2014, after Sequenta had raised $43.5m from investors including Index Ventures, Mohr Davidow Ventures and Foresite Capital, according to press releases…